35. Pemphigus Clinical trials / Disease details


Clinical trials : 98 Drugs : 126 - (DrugBank : 41) / Drug target genes : 23 - Drug target pathways : 168

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01930175
(ClinicalTrials.gov)
December 18, 201323/8/2013Study of Efficacy and Safety of VAY736 in Patients With Pemphigus VulgarisA Randomized, Partial-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VAY736 in the Treatment of Patients With Pemphigus VulgarisPemphigus VulgarisDrug: VAY736;Drug: PlaceboNovartis PharmaceuticalsNULLTerminated20 Years70 YearsAll13Phase 2United States;Austria;Bulgaria;Taiwan;Germany;Israel;Italy;United Kingdom
2EUCTR2013-001217-33-AT
(EUCTR)
25/11/201303/10/2013Study of efficacy and safety of VAY736 in patients with Pemphigus vulgarisA randomized, partial-blind, placebo-controlled trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of VAY736 in the treatment of patients with pemphigus vulgaris Pemphigus vulgaris
MedDRA version: 20.0;Level: LLT;Classification code 10052802;Term: Pemphigus vulgaris;System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: VAY736
INN or Proposed INN: ianalumab
Novartis Pharma Services AGNULLNot Recruiting Female: yes
Male: yes
32 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Taiwan;Austria;Bulgaria